Centrum Medyczne Neuromed Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Centrum Medyczne Neuromed Sp. z o.o. researchers are investigating therapies aimed at reducing cardiovascular risk, including studies on Atherosclerotic Cardiovascular Disease and obesity‑related heart conditions. The trials evaluate the efficacy and safety of novel oral agents to lower major cardiac events and improve metabolic health.
- Assessment of orforglipron for major cardiovascular outcomes
- Study of oral semaglutide’s impact on cardiovascular and metabolic parameters
- Investigation of weight‑loss interventions to mitigate heart disease risk
- Evaluation of cardiovascular safety in participants with chronic kidney disease
The site conducts 37 active trials with a team of 8 investigators, contributing to advances in heart health across Europe.
Immune System Diseases
The centre’s immune‑focused program examines how inflammation drives neurodegeneration, testing agents such as XPro1595 and GV1001 that target inflammatory pathways in early Alzheimer’s disease. These studies aim to determine whether modulating the immune response can slow cognitive decline.
- Anti‑inflammatory therapy in early Alzheimer’s disease
- Biomarker‑driven trials of immune modulation
- Safety evaluation of novel immunotherapies
- Exploration of inflammatory markers as treatment targets
By integrating immunology with neurology, the site supports innovative approaches to treat immune‑mediated disorders.
Nervous System Diseases
A broad spectrum of neurological conditions is under study at the Bydgoszcz facility, ranging from Alzheimer’s disease and Parkinson’s disease to Amyotrophic Lateral Sclerosis, Epilepsy, Migraine and multiple sclerosis. Trials seek new disease‑modifying drugs, symptom‑relief strategies, and long‑term safety assessments.
- Disease‑modifying agents for Alzheimer’s disease
- Motor fluctuation management in Parkinson’s disease
- Novel therapies for ALS progression
- Seizure frequency reduction in focal epilepsy
- Preventive and acute treatments for migraine
With 37 clinical studies underway, the site leverages eight investigators to advance neurological care across Europe.
Nutritional and Metabolic Diseases
Research on metabolic health includes trials targeting Obesity, Type 2 Diabetes, and related kidney disease. Agents such as Eloralintide and Orforglipron are being evaluated for weight reduction and cardiovascular outcome improvement, while metabolic control is also examined for its influence on neurodegeneration.
- Weight‑loss efficacy of eloralintide
- Cardiovascular outcome study of orforglipron in chronic kidney disease
- Metabolic safety of oral semaglutide in early cognitive impairment
- Impact of metabolic control on neurodegenerative disease progression
The multidisciplinary team of eight investigators conducts 37 trials, linking metabolic interventions to broader health benefits.
Mental Disorders
The facility focuses on behavioral and psychiatric symptoms associated with dementia, especially agitation associated with Alzheimer’s disease. Trials evaluate compounds like KarXT and AVP‑786 to improve patient calmness and caregiver outcomes while monitoring safety.
- Treatment of agitation in Alzheimer’s dementia
- Evaluation of KarXT for neuropsychiatric symptoms
- Safety and efficacy of AVP‑786 for behavioral management
- Long‑term tolerability of psychotropic agents in elderly populations
With a robust portfolio of 37 trials, the site’s eight investigators are advancing mental health care for neurodegenerative patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Praxis Precision Medicines Inc.2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.5trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Neuromed Sp. z o.o.
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetapir (18F) | 4 | Unknown | 2020-09-30 | 2025-12-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.